Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

Completed · Phase 1

Conditions studied: Healthy

In brief

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fasting conditions.

Key facts

Study ID

NCT00730197

Run by

Mylan Pharmaceuticals Inc

People needed

48

Starts

2007-02-01

Expected to finish

2007-03-01

Last updated by the study team

2008-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• PRACS Institute, Ltd. — Fargo, North Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.